Robbins LLP Informs Jasper Therapeutics Investors of Class Action Deadline Upcoming

Robbins LLP has issued an important reminder for investors regarding Jasper Therapeutics, Inc. (NASDAQ: JSPR) and an ongoing class action lawsuit. The firm is reaching out to stockholders who purchased or acquired Jasper securities between November 30, 2023, and July 3, 2025. This class action involves significant claims related to alleged misleading information regarding the company's commercial prospects, particularly concerning its lead product candidate, Briquilimab.

Jasper Therapeutics is a clinical-stage biotechnology firm dedicated to developing treatments for mast cell-driven diseases, which include Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and Asthma. The legal complaint centers on allegations that the company did not adequately disclose certain critical information to investors. Specifically, plaintiffs claim that Jasper lacked the appropriate controls and procedures to ensure that the third-party manufacturers it relied on were compliant with current Good Manufacturing Practices (cGMP) regulations necessary for clinical trials.

Further allegations in the lawsuit state that this failure increased the possibility that the results of current studies would be confounded, leading to a detrimental impact on both the clinical and commercial viability of Briquilimab and Jasper’s overall business prospects. This situation raises the specter of significant financial instability for the company, as it may necessitate disruptive cost-reduction measures to address these challenges.

On July 7, 2025, after these serious allegations became public, Jasper Therapeutics' stock plummeted by $3.73 per share, amounting to a staggering 55.1% drop, closing at $3.04 per share, highlighting the gravity of the situation for investors.

For those shareholders who wish to participate actively in the ongoing litigation, Robbins LLP encourages them to consider stepping up as lead plaintiffs. The role of a lead plaintiff is crucial as they represent the interests of all class members, steering the direction of the lawsuit. It's important to note that participating in the case is not a prerequisite for making a recovery—investors can choose to remain absent class members if they'd prefer.

The law firm operates on a contingency fee basis, meaning alumni and current clients do not incur any fees or expenses unless the case yields financial recovery for investors. Robbins LLP has a strong track record of advocating for shareholder rights since 2002, assisting investors in reclaiming losses while promoting improved governance within companies.

For further information on how to engage with the class action, interested parties can click the provided link or reach out directly to attorney Aaron Dumas, Jr. via email or contact a representative at (800) 350-6003. For those wishing to receive notifications about any potential settlement outcomes in this case or updates regarding corporate governance violations involving executives, signing up for Stock Watch can be beneficial.

In summary, the ongoing developments surrounding Jasper Therapeutics present critical implications for affected investors, and this class action offers a route to seek accountability and potential compensation for financial losses incurred during the specified period.

Robbins LLP looks forward to facilitating the participation of investors who believe they may have been impacted by these alleged misdeeds and working toward securing justice for affected shareholders.